UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study

Annals of the rheumatic diseases, 2022-12, Vol.81 (12), p.1661-1668

2022

Volltextzugriff (PDF)

Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study

Annals of the rheumatic diseases, 2021-09, Vol.80 (9), p.1147-1157

2021

Volltextzugriff (PDF)

Depression-, Pain-, and Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus

International journal of rheumatology, 2022-05, Vol.2022, p.6290736-8

2022

Volltextzugriff (PDF)

Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis

JAMA : the journal of the American Medical Association, 2007-07, Vol.298 (2), p.187

2007

Volltextzugriff (PDF)

Anti-NR2 antibodies, blood-brain barrier, and cognitive dysfunction

Clinical rheumatology, 2016-12, Vol.35 (12), p.2989-2997

2016

Volltextzugriff (PDF)

Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial

Annals of internal medicine, 2002-11, Vol.137 (9), p.726

2002

Volltextzugriff (PDF)

Non-criteria anti-phospholipid antibodies and cognitive impairment in SLE

Clinical rheumatology, 2016-01, Vol.35 (1), p.93-99

2016

Volltextzugriff (PDF)

Cognitive dysfunction in patients with systemic lupus erythematosus: a controlled study

Journal of rheumatology, 2011-06, Vol.38 (6), p.1020-1025

2011

Volltextzugriff (PDF)

Monitoring methotrexate toxicity in juvenile idiopathic arthritis

Journal of rheumatology, 2009-12, Vol.36 (12), p.2813-2818

2009

Volltextzugriff (PDF)

T cell costimulation: a rational target in the therapeutic armamentarium for autoimmune diseases and transplantation

Annual review of medicine, 2007-01, Vol.58 (1), p.347-358

2007

Volltextzugriff (PDF)

Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment

Annals of the rheumatic diseases, 2024-07, Vol.83 (11), p.1454-1464

2024

Volltextzugriff (PDF)

P136 Efficacy and safety of olokizumab in a phase III trial in patients with moderately to severely active RA inadequately controlled by TNF-α inhibitor therapy

Rheumatology (Oxford, England), 2021-04, Vol.60 (Supplement_1)

2021

Volltextzugriff (PDF)

Hypertrophic pachymeningitis in rheumatoid arthritis after adalimumab administration

Journal of rheumatology, 2006-11, Vol.33 (11), p.2344

2006

Volltextzugriff (PDF)

Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition

The New England journal of medicine, 2005-09, Vol.353 (11), p.1114-1123

2005

Volltextzugriff (PDF)

Trials are short, disease long: measuring drug utility beyond clinical trials

Journal of rheumatology, 2004-02, Vol.31 (2), p.205

Luggen, Michael L

2004

Volltextzugriff (PDF)

Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial

Annals of the rheumatic diseases, 2007-02, Vol.66 (2), p.228-234

2007

Volltextzugriff (PDF)

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

The Lancet (British edition), 2009-07, Vol.374 (9685), p.210-221

2009

Volltextzugriff (PDF)

Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy

Journal of rheumatology, 2012-08, Vol.39 (8), p.1546-1554

2012

Volltextzugriff (PDF)

15964 Randomized, double-blind, placebo-controlled, multiple-dose, phase 2b study to demonstrate the safety and efficacy of tildrakizumab, a high-affinity anti–interleukin-23p19 monoclonal antibody, in patients with active psoriatic arthritis

Journal of the American Academy of Dermatology, 2020-12, Vol.83 (6), p.AB165-AB165

2020

Volltextzugriff (PDF)

Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study

Sovremennai͡a︡ revmatologii͡a, 2023-04, Vol.17 (2), p.23-26

2023

Volltextzugriff (PDF)

Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study

Annals of the rheumatic diseases, 2012-06, Vol.71 (6), p.857-861

2012

Volltextzugriff (PDF)

Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab, a High-Affinity Anti–Interleukin-23P19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis

Skin (Milwood, N.Y.), 2020-09, Vol.4 (5), p.s43

2020

Volltextzugriff (PDF)

Non-parametric Class Completeness Estimators for Collaborative Knowledge Graphs—The Case of Wikidata

The Semantic Web - ISWC 2019, 2019, Vol.11778, p.453-469

2019

Volltextzugriff (PDF)

Visualizing Semantic Data

Encyclopedia of Big Data Technologies, 2019, p.1786-1792

2019

Volltextzugriff (PDF)

1 – 25 von 47

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(31)

Publikationsform

Sprache

Englisch
(47)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(36)
Humans
(34)
Life Sciences & Biomedicine
(33)
Biological And Medical Sciences
(25)
Medical Sciences
(25)
Rheumatology
(24)
Female
(22)
Male
(20)
Adult
(19)
Middle Aged
(18)
Double-Blind Method
(16)
Arthritis, Rheumatoid - Drug Therapy
(15)
Diseases Of The Osteoarticular System
(13)
Pharmacology. Drug Treatments
(13)
Aged
(12)
Treatment Outcome
(12)
Inflammatory Joint Diseases
(11)
Antirheumatic Agents - Therapeutic Use
(10)
Drug Therapy, Combination
(10)
Rheumatoid Arthritis
(10)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study

Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study

Depression-, Pain-, and Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus

Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis

Anti-NR2 antibodies, blood-brain barrier, and cognitive dysfunction

Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial

Non-criteria anti-phospholipid antibodies and cognitive impairment in SLE

Cognitive dysfunction in patients with systemic lupus erythematosus: a controlled study

Monitoring methotrexate toxicity in juvenile idiopathic arthritis

Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial

T cell costimulation: a rational target in the therapeutic armamentarium for autoimmune diseases and transplantation

Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment

P136 Efficacy and safety of olokizumab in a phase III trial in patients with moderately to severely active RA inadequately controlled by TNF-α inhibitor therapy

Hypertrophic pachymeningitis in rheumatoid arthritis after adalimumab administration

Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition

Trials are short, disease long: measuring drug utility beyond clinical trials

Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy

15964 Randomized, double-blind, placebo-controlled, multiple-dose, phase 2b study to demonstrate the safety and efficacy of tildrakizumab, a high-affinity anti–interleukin-23p19 monoclonal antibody, in patients with active psoriatic arthritis

Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study

Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study

Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab, a High-Affinity Anti–Interleukin-23P19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis

Non-parametric Class Completeness Estimators for Collaborative Knowledge Graphs—The Case of Wikidata

Visualizing Semantic Data

Suchergebnisse filtern